Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 11026 - 11050 of 12870 in total
CEQ508 is a Live Attenuated E. Coli Expressing Beta Catenin ShRNA currently being investigated to treat Familial Adenomatous Polyposis.
Investigational
Investigational
ATI-355 is a humanized anti-Nogo-A antibody developed by Novartis.
Investigational
Investigational
Investigational
Lexanersen is an antisense oligonucleotide under investigation for use as a disease-modifying therapy in Huntington's disease.
Investigational
Investigational
OPC1 is an oligodendrocyte progenitor cell therapy being investigated for the treatment of acute spinal cord injury.
Investigational
AP-101 is a recombinant human antibody directed against human misfolded superoxide dismutase 1.
Investigational
Investigational
Investigational
NSI-566 is a stem cell therapy consisting of human spinal cord-derived neural stem cells. Developed by Seneca Biopharma, it is being investigated for the treatment of amyotrophic lateral sclerosis (ALS), stroke, and chronic spinal cord injury (cSCI).
Investigational
PIKA rabies vaccine is a novel vaccine developed by YS Biopharma.
Investigational
Investigational
Investigational
Investigational
A version of tabituximab barzuxetan radiolabeled with yttrium-90.
Investigational
BHT-3034 is a DNA plasmid vaccine immunotherapy under investigation for the treatment of myasthenia gravis.
Investigational
SIS-101-ADO is a siRNA therapeutic under investigation for the treatment of Autosomal Dominant Osteopetrosis Type 2 (ADO2).
Investigational
NKX101 is an investigational allogeneic chimeric antigen receptor (CAR)-natural killer cell therapy.
Investigational
PBKR03 is a non-replicating recombinant adeno-associated virus serotype hu68 vector, containing a transgene encoding the human galactosylceramidase (GALC) enzyme.
Investigational
Displaying drugs 11026 - 11050 of 12870 in total